Syndax closes on $40m in funding

April 3, 2007 10:44 AM E-mail| |Comments ()| Text size +

Syndax, a Waltham biopharmaceutical company, announced today the closing of a $40 million Series A financing.

The firm, which focuses on developing and commercializing novel cancer therapies, said the funds will be used to develop a clinical pipeline.

The financing was co-led by Domain Associates LLC of Princeton, N.J., a venture capital firm with an exclusive focus on life sciences, and MPM Capital, another firm that invests in life sciences; MPM has offices in Boston.

"The financing allows us to execute plans to initiate several clinical trials this year," Syndax chief executive Joanna Horobin said in a statement. "We expect to announce shortly the in-licensing of a lead product candidate, which should move forward rapidly in development."
(By Chris Reidy, Globe staff)

Email this article

Invalid email address
Invalid email address

Sending your article

Your article has been sent.

Col3